The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer.
Category: Jorgensen, Lars Fruergaard
-
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.
-
Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
-
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy
Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.